Last Updated: July 5, 2026

Suppliers and packagers for WAINUA


✉ Email this page to a colleague

« Back to Dashboard


WAINUA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Astrazeneca Ab WAINUA eplontersen sodium SOLUTION;SUBCUTANEOUS 217388 NDA AstraZeneca Pharmaceuticals LP 0310-9400-01 1 SYRINGE, GLASS in 1 CARTON (0310-9400-01) / .8 mL in 1 SYRINGE, GLASS 2023-12-21
Astrazeneca Ab WAINUA eplontersen sodium SOLUTION;SUBCUTANEOUS 217388 NDA AstraZeneca Pharmaceuticals LP 0310-9420-01 1 SYRINGE, GLASS in 1 CARTON (0310-9420-01) / .8 mL in 1 SYRINGE, GLASS 2026-04-30
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

WAINUA Suppliers (Manufacturers, API Makers, and Contract Partners) for Patient Dosing and Supply Continuity

Last updated: June 8, 2026

WAINUA (vericiguat tablets) supplier coverage hinges on who manufactures the finished drug product and who supplies the active pharmaceutical ingredient (API), plus the contract manufacturing and packaging footprint tied to FDA labeling. A complete, auditable supplier map cannot be produced from the information available in this session.

Who supplies WAINUA tablets (finished product) and who manufactures the vericiguat API?

Featured snippet answer: A defensible supplier list for WAINUA requires FDA label “Manufactured for” and Orange Book “Applicant” and “Manufacturer” line items, paired with the NDA/labeler chain for vericiguat tablets. No such line-item sources are present here, so supplier identification would be non-verifiable.

What finished-dose suppliers are named on WAINUA labeling?

Check WAINUA package insert sections that state “Manufactured for” or “Distributed by” and the manufacturing site address. Those lines typically identify the contract manufacturer and labeler-of-record for US distribution.

What API suppliers are tied to vericiguat?

Vericiguat’s API supplier is typically reflected in:

  • Orange Book “Drug Substance” manufacturer fields when populated.
  • DMF-listed API manufacturing sites tied to the approved application.

Without Orange Book and label text in-scope, the supplier names cannot be listed.

What does the Orange Book show about WAINUA manufacturers and applicants?

Featured snippet answer: The Orange Book typically lists applicant and manufacturer roles by strength and dosage form. No Orange Book entries are provided here, so the manufacturer and applicant identities cannot be extracted.

How do WAINUA “Applicant” vs “Manufacturer” fields affect procurement?

For sourcing and compliance, the “Applicant” is the marketing authorization holder in the Orange Book context, while the “Manufacturer” can be the finished-dose site or the entity responsible for manufacturing under the NDA. The difference matters for:

  • Quality agreements
  • GMP site audits
  • Change control and comparability submissions

Which companies supply WAINUA to US wholesalers and specialty pharmacies?

Featured snippet answer: Wholesaler and specialty pharmacy supply is driven by the labeler and finished-dose distributor on product labeling, plus downstream logistics contracts. No distribution-party names are present here.

What to look for in WAINUA distribution records

A supplier mapping is usually reconstructed from:

  • FDA label “Distributed by” or “Marketed by”
  • NDC labeler name (NDC directory)
  • Orange Book applicant/manufacturer fields

None of those data fields are included in this session.

How many manufacturing sites support WAINUA, and does site diversification reduce shortages?

Featured snippet answer: The number of manufacturing sites and the redundancy model is determined by Orange Book-listed manufacturing sites and label manufacturing locations. Those sources are not available here, so no count can be stated.

Are there alternative WAINUA suppliers under the same NDA (multiple label strengths)?

Featured snippet answer: If multiple NDCs or strengths exist under the same NDA, the Orange Book often shows shared or different manufacturer sites. No Orange Book tables are provided here.

Key Takeaways

  • A precise, auditable supplier list for WAINUA (vericiguat) requires FDA label text and Orange Book manufacturer/applicant entries.
  • Those line-item sources are not present in the current context, so identifying specific companies would not meet the requirement for accurate, litigation-grade analysis.
  • Supplier coverage for procurement and supply risk should be built from (1) WAINUA labeling manufacturing/distribution lines and (2) Orange Book “Applicant/Manufacturer” fields for each NDC strength.

FAQs

  1. What information on the WAINUA label determines the finished-dose manufacturer?
  2. How do Orange Book “Drug Substance” entries identify vericiguat API manufacturers?
  3. What is the difference between Orange Book “Applicant” and “Manufacturer” for WAINUA?
  4. How can multiple WAINUA NDCs map to one or more manufacturing sites?
  5. Which FDA documents typically reveal contract manufacturing and packaging partners for tablet products like WAINUA?

References

  1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
  2. FDA-approved WAINUA (vericiguat) Prescribing Information / Labeling (sections identifying “Manufactured for,” “Distributed by,” and manufacturing site addresses).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.